Effect of Wuzhi capsules on pharmacokinetics of tacrolimus

MI Li,WEI Hua, LI Jingchao, QIN Shixin, and MAO Jianhui

Medical Journal of the Chinese People Armed Police Forces ›› 2016, Vol. 27 ›› Issue (3) : 240-242.

PDF(650 KB)
PDF(650 KB)
Medical Journal of the Chinese People Armed Police Forces ›› 2016, Vol. 27 ›› Issue (3) : 240-242.
ORIGINAL ARTICLES

Effect of Wuzhi capsules on pharmacokinetics of tacrolimus

  • MI Li1,WEI Hua2, LI Jingchao3, QIN Shixin4, and MAO Jianhui1
Author information +
History +

Abstract

Objective To evaluate the effect of different doses of Wuzhi capsules on the pharmacokinatics of Tacrolimus in healthy human body. Methods 40 healthy volunteers were divided into 5 groups, and 0, 1, 2, 6, 8 capsules of Wuzhi capsules were given to each group accordingly after 2 mg of tacrolimus was given systematically. Venous blood was collected before and at different time points after drug administration. Blood samples were collected in anti-coagulation tubes and stored till analysis. Results The dose of tacrolimus was increased with the increase of the dose of Wuzhi capsules AUC0→t, Tmax, and the largest were (459.3±114.2)ng·h/ml and(3.125±1.356)h, respectively, and Cmax was the largest after taking two capsules (43.539±10.656) ng/ml. The CL/F ratio decreased from 51.67% to 27.09% when the dose of Wuzhi capsules increased from 1 capsule to 8 capsules. Conclusions The metabolic rate of tacrolimus decreases, the clearance rate decreases and the blood concentration increases when Wuzhi capsules are administered together with tacrolimus.

Key words

Tacrolimus / Wuzhi capsules / pharmacokinetics / HPLC

Cite this article

Download Citations
MI Li,WEI Hua, LI Jingchao, QIN Shixin, and MAO Jianhui. Effect of Wuzhi capsules on pharmacokinetics of tacrolimus[J]. Medical Journal of the Chinese People Armed Police Forces. 2016, 27(3): 240-242

References

[1]陈 超,邬义强,林述龙.五酯胶囊联合西药治疗慢性乙型肝炎42例疗效观察[J].云南中医中药杂志,2008, 29(11):23-24.
[2] Anglicheau D, Legendre C, Beanne P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update[J].Pharmacogenomics,2007,8(7):835-849.
[3] MacPhee I A, Holt D W. A. pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype [J]. Transplantation, 2008, 85(2):163-165.
[4] 刘丽娟,赖雁威,李慧云,等. 肝移植患者他克莫司谷血药浓度监测意义和临床个体化用药调节[J]. 现代生物医学进展,2015,25(12):1026-1030.
[5] Park J Y, Shin H K,Choi Y W,et al. Gomisin A induces Ca2+-dependent activation of eNOS in human coronary artery endothelial cells [J]. J Ethnopharmaco1, 2009, 125(2):291-296.
[6] 徐艳霞.中草药对肝细胞色素P450的作用[J].中国药理通讯,2005,22(3):64-68.
PDF(650 KB)

Accesses

Citation

Detail

Sections
Recommended

/